Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters [PDF]
European Journal of Histochemistry, 2021 The sialic acid-binding immunoglobulin-type lectin Siglec-15 is a promising target to cancer immunotherapy in several tumor types. The present study aimed to investigate Siglec-15 expression in gastric cancer (GC) patient tissue and to evaluate its ...
Michael Williams Leal Quirino +9 more
doaj +2 more sources
Anti‐Siglec‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats [PDF]
JBMR Plus, 2023 Rapid and extensive sublesional bone loss after spinal cord injury (SCI) is a difficult medical problem that has been refractory to available interventions except the antiresorptive agent denosumab (DMAB). While DMAB has shown some efficacy in inhibiting
Yuanzhen Peng +13 more
doaj +2 more sources
Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor [PDF]
Bone ResearchDNAX-associated protein 12 kD size (DAP12) is a dominant immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptor that activates costimulatory signals essential for osteoclastogenesis.
Hideyuki Kobayashi +11 more
doaj +2 more sources
Killing two birds with one stone: Siglec-15 targeting integrated bioactive glasses hydrogel for treatment of breast cancer bone metastasis [PDF]
Materials Today BioBone metastasis is a fatal consequence of breast cancer that occurs when patients fail to respond to conventional therapies and mainly result from a vicious cycle involving dysregulated bone homeostasis and uncontrolled tumor growth.
Chengkuan Liu +6 more
doaj +2 more sources
Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy [PDF]
ImmunoTargets and TherapyQin Liu,1,* Lin Li,1,* Siji Nian,1 Xiaoke Sun,2 Xiyuan Guo,1 Chengwen Li,1 Zhihui Yang,3 Yingchun Ye,1 Qing Yuan1,4 1Public Center of Experimental Technology, The School of Basic Medical Sciences, Southwest Medical University, Luzhou ...
Liu Q +8 more
doaj +2 more sources
Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec‐15 axis in immune escape [PDF]
Cancer CommunicationsBackground Metabolic reprograming and immune escape are two hallmarks of cancer. However, how metabolic disorders drive immune escape in head and neck squamous cell carcinoma (HNSCC) remains unclear.
Xin‐Yu Zhang +7 more
doaj +2 more sources
Development of an immunohistochemical assay for Siglec-15. [PDF]
Lab Invest, 2022 Siglec-15, a member of sialic-acid binding immunoglobulin type lectins, is normally expressed by myeloid cells and upregulated in some human cancers and represents a promising new target for immunotherapy.
Shafi S +17 more
europepmc +4 more sources
Siglec-15 promotes progression of clear renal cell carcinoma [PDF]
Chinese Medical Journal, 2021 Wen-Bo Yang +5 more
doaj +2 more sources
Regulation of Receptors Siglec-11 and Siglec-15 by MicroRNAs and their Overall Effect on Glioblastoma [PDF]
, 2022 Introduction: Glioblastoma is a fast growing and aggressive type of brain tumour. It is the most common type of brain tumour in adults. Although there are developments in current therapies, patient outcomes remain poor.
Al-Azzawi, Dema
core +1 more source
Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric Cancer. [PDF]
Int J Mol SciGastric cancer remains a major global health burden, with limited response rates to current immunotherapies targeting the programmed death-ligand 1 (PD-1/PD-L1) axis.
Cozac-Szőke AR +13 more
europepmc +2 more sources